The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who […]
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted AstraZeneca’s applications for cancer treatments moxetumomab pasudotox and Lynparza (olaparib). The FDA has accepted AstraZeneca and MedImmune’s biologics license application […]
US researchers have developed a new RNA-based therapy to help the immune system target a mosquito-borne disease caused by the West Nile virus. Led by Yale University, the team tested the therapy in mice and […]
AstraZeneca and MedImmune, its global biologics research and development arm, have announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox for adult patients with hairy […]
Pfizer has announced positive results from its Phase III study of experimental drug tafamidis in patients with transthyretin cardiomyopathy. According to topline results, the drug met its primary endpoint, demonstrating a statistically-significant reduction in the […]